Key Highlights

  • Acumen Pharmaceuticals is trading down 85.77% at $0.33 after its Phase 2 Alzheimer's trial missed the primary endpoint.
  • Solowin Holdings is trading down 44.73% at $2.05 following a 1-for-200 reverse stock split.
  • Davion Healthcare is trading down 28.25% at $1.93, with no company announcement identified for the move.
  • The average decline across the five stocks is 42.74% (calculated), and the spread between the largest and smallest is 58.43 percentage points (calculated).
  • Four of the five stocks have no same-day company announcement identified.

Which Penny Stocks Are Falling the Most Today?

Five penny stocks, all priced under $5, are posting the steepest declines in this ranking on Oct 30, 2026, ordered by the size of the percentage drop. Acumen Pharmaceuticals (NASDAQ:ABOS) is trading down 85.77% at $0.33, Solowin Holdings (NASDAQ:AXG) is down 44.73% at $2.05, Davion Healthcare (NASDAQ:DAVI) is down 28.25% at $1.93, MDB Capital Holdings (NASDAQ:MDBH) is down 27.62% at $1.31 and Vivakor (NASDAQ:VIVK) is down 27.34% at $1.09.

The percentage moves are measured against each stock's prior close, so the bases differ, and two of the names, Solowin and Vivakor, have recently gone through reverse stock splits that make older price comparisons unreliable. The list is a ranking of price moves, not a view on any company's prospects.

The catalysts are uneven. Only Acumen has a clear company announcement behind its slide, a failed clinical trial. For the other four, the research behind this article did not identify a company-specific announcement dated today, so the moves are described below without an assigned cause.

1. Acumen Pharmaceuticals: why is the stock down 85.77% after the ALTITUDE-AD trial?

Acumen is trading down 85.77% at $0.33 after reporting topline results from its Phase 2 ALTITUDE-AD trial of sabirnetug in early Alzheimer's disease. The study of 542 participants missed its primary endpoint, a change in the iADRS score at 18 months, at both the 35 mg/kg and 50 mg/kg doses, and key secondary measures also failed to reach statistical significance.

The clinical-stage company said it will stop developing sabirnetug and evaluate strategic options, including its Enhanced Brain Delivery program. Cash and marketable securities were $110.2 million at June 30, 2026, and the company said that supported operations into early 2027. Based on about 72.3 million shares, the current price implies a Market Value near $24 million, a figure that is a rough estimate.

2. Solowin Holdings: what is behind the 44.73% drop after the reverse split?

Solowin is trading down 44.73% at $2.05, against a prior close near $3.71. No separate company announcement was identified beyond the 1-for-200 reverse split that was announced on Oct 27 to lift the shares above Nasdaq's $1.00 minimum bid requirement.

The Hong Kong-based company combines brokerage services with digital assets, stablecoins and AI infrastructure projects. It reported fiscal 2026 Revenue growth of about 895% to roughly $28 million, alongside a net loss of about $13 million. Sources differ slightly on those totals, and the quoted 52-week range mixes pre-split and post-split prices, so it should not be compared directly with today's level.

3. Davion Healthcare: why is the newly Listed Stock down 28.25%?

Davion is trading down 28.25% at $1.93, and no company press release or filing explaining the move was identified. The shares began trading on Nasdaq through a direct listing in late October, and one data page showed a $6.00 close on Oct 23 and a price near $4.04 on Oct 26. Those prices come from a single unverified page.

The Irish company is pre-revenue and develops at-home screening tools, led by the BreastCheck test. It reported an operating loss of about 0.8 million euros for 2025, and no cash balance was disclosed in the sources reviewed. At about 25 million shares, the current price implies a market value near $48 million, a rough calculation.

4. MDB Capital Holdings: what explains the 27.62% slide with no news?

MDB Capital is trading down 27.62% at $1.31, with the prior close working out to roughly $1.81. No company-specific announcement for the decline was identified, and the latest update found was its second-quarter report on Aug 13.

The company runs a public venture platform that includes a broker-dealer, the PatentVest intellectual property Business and a small-molecule senescence platform. It reported a first-half 2026 net loss of about $16.1 million, much of it from non-cash items, and net cash, current Assets and marketable securities near $12.1 million at the end of the second quarter. The revenue and 52-week range figures available are from early September and may be stale.

5. Vivakor: is the 27.34% fall below its 52-week low tied to the reverse split?

Vivakor is trading down 27.34% at $1.09, from a prior close of roughly $1.50, which puts it below the split-adjusted 52-week low of $1.14. No company announcement dated today was identified. A 1-for-15 reverse split took effect on Oct 5, 2026, and the prior session's Volume was light.

The company provides Crude Oil transportation, storage and remediation services. It signed a letter of intent on Oct 9 for a proposed $40 million Acquisition of Direct Midstream and said on Oct 23 that Due Diligence was complete. The available sources do not link any of those updates to today's decline, and the market value was only about $1.1 million at the last close.

Penny Stock Plunge Scorecard: Average Decline, Spread and Price Gap

The five stocks are down an average of 42.74% (calculated), but that figure is dominated by Acumen. The gap between the biggest decline, 85.77%, and the smallest, 27.34%, is 58.43 percentage points (calculated). The four stocks other than Acumen are clustered more tightly, between 27.34% and 44.73%.

Prices also vary widely. Solowin's $2.05 share price is about 6.21 times Acumen's $0.33 (calculated), yet all five remain under the $5 Penny Stock line. The bases differ across the group because two stocks trade on post-reverse-split prices, and the only decline with a plainly stated trigger is Acumen's trial failure. Four of the five moves lack an identified announcement, which makes them harder to interpret.

What to Watch Next: Acumen Biomarker Data and Listing Milestones

Acumen said additional fluid biomarker and imaging data are due in the coming weeks, along with any detail on cash conservation and its strategic options. The company has not given a revised runway beyond the early 2027 timeframe it cited from its June balance.

For Vivakor, the next dated markers are a definitive Direct Midstream agreement, with no date identified, and the first-quarter 2027 start-up target for its Houston remediation center. Solowin will be judged on whether it holds above the $1.00 bid threshold after its split. For Davion and MDB Capital, no dated release was identified, though Davion's first periodic filings as a public company and MDB's next quarterly update are the likely sources of fresh information.